Physician profile
Ann E Ballen
NPI 1760481022
$7,664.75
in general payments reported to CMS, 2019-2025
29 companies · $1,362 in 2025
The $1,362 reported for 2025 was more than what 83% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,262 · 2020: $523 · 2021: $1,024 · 2022: $1,055 · 2023: $1,458 · 2024: $981 · 2025: $1,362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,801.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $1,047.59 | 2023-2025 | Ahmed Glaucoma Valve, Kahook Dual Blade, Streamline |
| Alcon Vision LLC | $907.59 | 2019-2025 | Tryptyr, Argos, Clareon Panoptix Pro |
| Abbvie INC. | $893.26 | 2022-2025 | Durysta, Lumigan, Alphagan P |
| Allergan, INC. | $847.87 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $583.55 | 2021-2025 | Acthar |
| Johnson & Johnson Surgical Vision, INC. | $437.22 | 2019-2025 | Tecnis Simplicity, Tecnis Iol, Tecnis Iol |
| Aerie Pharmaceuticals, INC. | $386.11 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $352.51 | 2019-2021 | |
| Glaukos Corporation | $317.43 | 2019-2025 | Idose, Idosetr |
| Horizon Therapeutics Plc | $251.67 | 2021-2023 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $230.27 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $216.68 | 2019-2022 | |
| Oyster Point Pharma, INC. | $197.99 | 2022-2024 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $159.40 | 2019 | |
| Novartis Pharmaceuticals Corporation | $153.93 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $152.06 | 2019-2022 | |
| Lensar, INC. | $76.53 | 2025 | Lensar Laser System |
| Rxsight INC | $66.02 | 2024-2025 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Bausch & Lomb Americas INC. | $65.40 | 2024-2025 | Vyzulta, Miebo, Scoutpro Osmolarity System |
| Sight Sciences, INC. | $64.28 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Ocular Therapeutix, INC. | $49.78 | 2021-2025 | Dextenza |
| Thea Pharma INC. | $48.54 | 2023-2024 | Iyuzeh |
| Rayner Intraocular Lenses Limited | $45.22 | 2025 | Omidria |
| Iridex Corporation | $23.91 | 2019 | |
| Dompe US, INC. | $20.62 | 2021 | |
| Travere Therapeutics, INC. | $19.37 | 2022 | |
| Mallinckrodt Enterprises LLC | $18.53 | 2019 | |
| Shire North American Group INC | $16.80 | 2019 | |
| Eyevance Pharmaceuticals LLC | $14.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Ballen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.